CSBio CSBio

X
[{"orgOrder":0,"company":"Cryostem","sponsor":"Rheos Medicines","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Rheos Medicines Forms Research Collaboration With CRYOSTEM to Evaluate MALT1\u2011Targeted Therapeutics for Graft-versus-Host-Disease","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Cryostem"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            The goal of the collaboration is to provide biological resources from HSC patients in order to evaluate MALT1-targeted therapeutics, including Rheos’s lead product candidate, RHX-317, for Graft-versus-Host Disease, based on functional immunologic profiling of patients.

            Lead Product(s): RHX-317

            Therapeutic Area: Immunology Product Name: RHX-317

            Highest Development Status: IND Enabling Product Type: Small molecule

            Partner/Sponsor/Collaborator: Rheos Medicines

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration October 27, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY